Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003452 | 0.93 | BMP1 (0.89) | BMP1 | |
| SCHEMBL7001896 | 0.90 | BMP1 (1.00) | BMP1 | |
| SCHEMBL7008058 | 0.88 | BMP1 (1.00) | BMP1 | |
| SCHEMBL7002992 | 0.85 | BMP1 (1.00) | BMP1 | |
| SCHEMBL6999380 | 0.85 | BMP1 (1.00) | BMP1 | |
| SCHEMBL7000638 | 0.84 | BMP1 (1.00) | BMP1 | |
| SCHEMBL7003670 | 0.84 | BMP1 (0.72) | BMP1 | |
| SCHEMBL7004497 | 0.83 | BMP1 (0.89) | BMP1 | |
| SCHEMBL966010 | 0.83 | BMP1 (1.00) | BMP1 | |
| SCHEMBL1115835 | 0.81 | BMP1 (0.77) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210107878-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10927081-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10894774-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10882827-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1154992-A4 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1154992-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050390-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | BMP1 2470/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | BMP1 4106/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | BMP1 260/4885 |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | BMP1 730/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | BMP1 2724/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | BMP1 659/4885 |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-10894774-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-20210107878-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | BMP1 260/4885 |
| US-10927081-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-10882827-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | BMP1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.